The start-up company SeraGene, spun out of NMIN and co-founded by …
Previous
Next
Latest news...
For their contributions to the development of an mRNA-based COVID vaccine, …
A new special issue of the American Chemical Society journal Molecular …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the eight …
https://youtu.be/4eg6Y8x1JXE?list=PLh7NyssbO61nky9vVCrRsJG9izYAl5VV6Video profile of GGIA Laureate Acuitas A research team assembled in …
NMIN spin-off company NanoVation Therapeutics™ (NTx) is growing rapidly and is …
Canadian nanomedicine scientist and NMIN founder Dr. Pieter Cullis, together with …
The NanoMedicines Innovation Network (NMIN) is pleased to announce eight new …
Canadian nanomedicine scientist and NMIN founder Dr. Pieter Cullis, together with …
NMIN’s Founding Director, Dr. Pieter Cullis, has been named an Officer …
Entos Pharmaceuticals Inc., led by NMIN researcher Dr. John Lewis, has …
Canadian scientist Dr. Pieter Cullis, together with his peers Drs Katalin …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the recipient …
As of 19 October 2021, NMIN has a new Manager, Research …
https://youtu.be/AuEkO4Ge-q4 Thomas Madden (Acuitas) interviewed on Global TV Acuitas Therapeutics, the …
“There is no time like the present to try to achieve …
NMIN
about us
Advancing research, innovation and training in nanomedicines to maintain Canada as the world leader in the field.
The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NMIN brings Principal Investigators from institutions across Canada together with companies and not-for-profit research and granting institutions in a network committed to expanding and improving Canada’s position as a global leader in nanomedicines R&D.
NMIN is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
NMIN
Our focus
Develop nanomedicines
that enhance the therapeutic properties of small molecule drugs, and enable gene therapies.
Develop new diagnostics
that enable more precise disease detection and treatment, based on nanotechnology.
Train scientists
in the technology and business of nanomedicines, guided by market needs for HQP with skills required by the R&D community.
Translate nanomedicine
products and technologies, by implementing a cohesive IP and commercialization strategy.
NMIN
Management Team
Christine Allen
Scientific Director & CEO
Gilbert Walker
Associate Scientific Director
Diana Royce
Executive Director
NMIN
Contact
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
info@nanomedicines.ca